Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H7XD | ISIN: US8106481059 | Ticker-Symbol: 2SX
Tradegate
31.03.25
15:56 Uhr
2,440 Euro
-0,120
-4,69 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
SCPHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SCPHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,3602,44022:01
2,3402,52022:00

Aktuelle News zur SCPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.03.scPharmaceuticals (NASDAQ:SCPH) Given New $12.00 Price Target at Maxim Group4
21.03.HC Wainwright Reiterates "Buy" Rating for scPharmaceuticals (NASDAQ:SCPH)3
20.03.Analyst Expectations For scPharmaceuticals' Future2
20.03.ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 202513
19.03.scPharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans1
19.03.scPharmaceuticals Inc. - 10-K, Annual Report1
19.03.scPharmaceuticals GAAP EPS of -$0.35 beats by $0.03, revenue of $12.2M beats by $0.02M5
SCPHARMACEUTICALS Aktie jetzt für 0€ handeln
19.03.scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update89scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024...
► Artikel lesen
19.03.scPharmaceuticals Inc. - 8-K, Current Report1
12.03.scPharmaceuticals Inc.: scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 20253
07.03.FDA approves scPharmaceuticals' Furoscix sNDA for oedema in CKD12
07.03.H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target11
07.03.ScPharma: FDA Approves FUROSCIX For Treating Edema In Chronic Kidney Disease Patients7
03.03.scPharmaceuticals (NASDAQ:SCPH) Earns "Buy" Rating from HC Wainwright17
10.01.scPharmaceuticals reports preliminary Q4 numbers11
10.01.scPharmaceuticals prognostiziert 99% Umsatzsprung im vierten Quartal3
10.01.scPharmaceuticals projects 99% Q4 revenue jum1
10.01.scPharmaceuticals Inc.: scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results325Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter...
► Artikel lesen
10.01.scPharmaceuticals Inc. - 8-K, Current Report-
31.12.24scPharmaceuticals Inc. - 10-Q/A, Quarterly Report1
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1